AFFYMAX INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2010-11-29: Form 8-K; Period of report 2010-11-29; Description 2.02 Results of Operations and Financial Condition; 8.01 Other Events; Details 2.02.
- 2010-11-16: Form 8-K; Period of report 2010-11-15; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2010-11-05: Form 8-K; Period of report 2010-11-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2010-10-18: Form 8-K; Period of report 2010-10-15; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2010-11-29 | 8-K | 2010-11-29 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 Affymax, Inc. (the “Company”) expects to have cash and investments of approximately $115 million at December 31, 2010, which it believes will enable the Company to maintain current planned operations well into 2012. 8.01 On November 29, 2010, the Company and Takeda Pharmaceutical Company, Ltd (“Takeda”) confirmed the U.S. registration strategy for Hematide™/peginesatide following the meeting with the U.S. Food and Drug Administration. | a10-21800_18k.htm |
| 2010-11-16 | 8-K | 2010-11-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective November 15, 2010, Herb Cross, who is 39 years old, was appointed Vice President, Finance and Chief Accounting Officer of Affymax, Inc. (the “Company”). | a10-21334_18k.htm |
| 2010-11-05 | 8-K | 2010-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2010, Affymax, Inc. issued a press release announcing its financial results for the quarterly period ended September 30, 2010. | a10-20722_18k.htm |
| 2010-10-18 | 8-K | 2010-10-15 | 8.01 Other Events | 8.01 As disclosed previously, we have entered into a Common Stock Purchase Agreement, or Purchase Agreement, as amended, with Azimuth Opportunity Ltd., or Azimuth, pursuant to which we may, from time to time and subject to the terms and limitations set forth in the Purchase Agreement, sell Azimuth shares of our common stock. | a10-19450_18k.htm |
| 2010-10-06 | 8-K | 2010-10-06 | 8.01 Other Events | 8.01 On October 6, 2010, we announced the decision of the arbitration panel in our binding arbitration with certain subsidiaries of Johnson & Johnson (“J&J”). | a10-19039_18k.htm |
| 2010-09-24 | 8-K | 2010-09-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 *The shares vest and become exercisable in a series of forty-eight (48) successive equal monthly installments over the four (4) year period measured from September 22, 2010. | a10-18406_18k.htm |
| 2010-09-20 | 8-K | 2010-09-17 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a10-18112_18k.htm |
| 2010-09-15 | 8-K | 2010-09-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On September 13, 2010, Affymax, Inc. (the “Company”) received a written notice from Steven Love, the Vice President, Finance and principal accounting officer, of his resignation as an officer and employee of the Company effective as of October 31, 2010. | a10-17905_18k.htm |
| 2010-08-05 | 8-K | 2010-08-04 | 2.02 Results of Operations and Financial Condition | 2.02 On August 4, 2010, Affymax, Inc. issued a press release announcing its financial results for the quarterly period ended June 30, 2010. | a10-15369_18k.htm |
| 2010-06-21 | 8-K | 2010-06-21 | 8.01 Other Events | 8.01 On June 21, 2010, Affymax, Inc. (the “Company”), Takeda Global Research & Development, Inc. and Takeda Pharmaceutical Company, Ltd (“Takeda”) announced preliminary top line results from the Hematide™/peginesatide Phase 3 clinical program for the treatment of anemia associated with chronic renal failure anemia. | a10-12318_18k.htm |
| 2010-05-26 | 8-K | 2010-05-24 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On May 24, 2010, Affymax, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Meeting”) at 4015 Miranda Avenue, Palo Alto, CA 94304. | a10-10950_18k.htm |
| 2010-05-25 | 8-K | 2010-05-20 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a10-10783_18k.htm |
| 2010-05-10 | 8-K | 2010-05-06 | 2.02 Results of Operations and Financial Condition | 2.02 On May 6, 2010, Affymax, Inc. issued a press release announcing its financial results for the quarterly period ended March 31, 2010. | a10-9708_18k.htm |
| 2010-04-13 | 8-K | 2010-04-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective April 12, 2010, John A. Orwin, who is 45 years old, was appointed President and Chief Operating Officer of Affymax, Inc. (the “Company”). | a10-8041_18k.htm |
| 2010-03-04 | 8-K | 2010-03-04 | 2.02 Results of Operations and Financial Condition | 2.02 On March 4, 2010, Affymax, Inc. issued a press release announcing its financial results for the year ended December 31, 2009. | a10-5155_18k.htm |
| 2010-01-11 | 8-K | 2010-01-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 * The shares vest and become exercisable in a series of forty-eight (48) successive equal monthly installments over the four (4) year period measured from January 1, 2010. | a10-1505_18k.htm |